Equasens: Dominique Pautrat Appointed as Chairman of the Board
Equasens announced on Wednesday the appointment of Dominique Pautrat as the chairman of the board, succeeding Thierry Chapusot whose term has expired. This transition is accompanied by the arrival of four new board members.
Dominique Pautrat, Former CEO, Takes Over as Chairman
Dominique Pautrat, who led Equasens as CEO from 2010 to 2022, becomes the chairman of the board, replacing Thierry Chapusot, the founder of the group and chairman since 2010. Pautrat retains an in-depth knowledge of the group which he helped develop during his tenure as executive director, marked by strong growth and diversification into other health professions as well as expansion into Europe, specifically in England and Italy. Since 2022, he has been serving as the chairman at La Coopérative Welcoop and Marque Verte Santé, the parent holding of Equasens, while remaining a board member of the group.
Four New Board Members Elected at the General Assembly
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The general assembly approved the co-option of Sylvie Ortillon, a pharmacist, as a board member replacing Emilie Lecomte following her resignation. Three additional members were also appointed to the board: Céline Dargent, a chartered accountant, consultant, and auditor specializing in sustainable development, as an independent board member; Vincent Monestel, a pharmacist; and François-Pierre Marquier, deputy CEO of Equasens and director of the Pharmagest division.
SectorLogiciels et services numériques›Logiciels et données de santé (healthtech)
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 181,8 millions d'euros
Quarterly revenue: 181,8 millions d'euros
Revenue growth: 5,6 %
Guidance from the release
« Sur les neuf premiers mois de l'année, le Groupe affiche une bonne performance. [...] Avec la montée en puissance du Ségur Vague 2 au quatrième trimestre, nous restons pleinement mobilisés pour renforcer notre dynamique commerciale d'ici la fin d'année et préparer les relais de croissance de 2027. »
Risks mentioned
Environnement plus exigeant pour les Divisions E-CONNECT et MEDICAL SOLUTIONS
Division E-CONNECT face à tensions sur les chaînes d'approvisionnement et fluctuations de prix de composants
Contexte de taux de financement élevés et volatils affectant la Division FINTECH
Opportunities identified
Montée en puissance du programme Ségur Vague 2 au T4 2026 dans les Divisions AXIGATE LINK et MEDICAL SOLUTIONS
Intégration de l'Intelligence Artificielle au cœur des logiciels métier et stratégie de commercialisation SaaS en Europe
Forte dynamique du secteur Hôpital (+81,8% sur 9 mois) avec référencements Ségur obtenus pour déploiements T4 2026
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
